SHANDONG BUCHANG PHARMACEUTICALS CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.85 CNY | -7.26% |
|
-5.20% | -6.82% |
| Sales 2022 | 14.95B 2.06B 172B | Sales 2023 | 13.25B 1.83B 152B | Capitalization | 18.81B 2.6B 216B |
|---|---|---|---|---|---|
| Net income 2022 | -1.66B -229M -19.07B | Net income 2023 | 319M 44.02M 3.67B | EV / Sales 2022 | 1.58 x |
| Net Debt 2022 | 422M 58.22M 4.85B | Net Debt 2023 | 2.1B 290M 24.21B | EV / Sales 2023 | 1.58 x |
| P/E ratio 2022 |
-14
x | P/E ratio 2023 |
59
x | Employees | 8,491 |
| Yield 2022 |
4.57% | Yield 2023 |
-
| Free-Float | 40.74% |
More Fundamentals
* Assessed data
More news
| 1 day | -7.26% | ||
| 1 week | -5.20% | ||
| Current month | -5.32% | ||
| 1 month | -5.20% | ||
| 3 months | -0.88% | ||
| 6 months | -5.93% | ||
| Current year | -6.82% |
1 week
15.39
17.11
1 month
15.3917.20
Current year
14.1518.13
1 year
14.1523.30
3 years
14.1528.38
5 years
14.1533.12
10 years
14.1591.96
| Managers | Title | Age | Since |
|---|---|---|---|
Bao Cai Wang
DFI | Director of Finance/CFO | 60 | 11/12/11 |
Chao Zhao
PSD | President | 56 | 11/12/11 |
Xi Fang Wang
CTO | Chief Tech/Sci/R&D Officer | 65 | 26/17/26 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Tao Zhao
CHM | Chairman | 58 | 11/12/11 |
Chun Yi Li
BRD | Director/Board Member | 59 | 11/12/11 |
Yu Gao
BRD | Director/Board Member | 50 | 11/12/11 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.41% | 2 M€ | -16.59% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 15.85 | -7.26% | 27,112,960 |
| 25/24/25 | 17.09 | +1.06% | 5,629,871 |
| 24/24/24 | 16.91 | -0.70% | 5,043,206 |
| 23/24/23 | 17.03 | +1.19% | 5,884,721 |
| 22/24/22 | 16.83 | +0.66% | 5,572,565 |
End-of-day quote Shanghai S.E., April 26, 2024
More quotes
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD. is a China-based company principally engaged in the research, development, manufacture and distribution of Chinese patent medicines. The Companyâs main products are compound traditional Chinese medicines, including cerecarton capsules,wenxin granules, as well as danhong injections, among others. Its products are mainly applied to the fields of cardio-cerebrovascular diseases and gynecological diseases. The Company distributes its products within domestic market and to overseas markets, with North China, East China and Central China as its major markets.
Sector
Pharmaceuticals
Calendar
23/08/2024
- Q2 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -6.82% | 2.42B | |
| +35.04% | 5.92B | |
| -15.13% | 4.51B | |
| -9.75% | 3.15B | |
| +2.14% | 3.1B | |
| +47.87% | 1.97B | |
| -7.89% | 1.68B | |
| +0.09% | 1.65B | |
| -12.97% | 1.53B | |
| +33.40% | 1.38B |
- Stock Market
- Equities
- 603858 Stock
